Chiquita Brooks-LaSure, CMS director (Caroline Brehman/CQ Roll Call via AP Images)
Ahead of lecanemab decision, Alzheimer's groups petition CMS to reverse coverage policy
Aduhelm’s successor is now weeks away from its PDUFA date — and several advocacy groups are arguing for the reversal of a controversial CMS policy.
The groups, including the Azheimer’s Association and a number of doctors and medical professionals, are advocating for CMS to reconsider its January announcement that restricts the reimbursement of Aduhelm and other anti-amyloid monoclonal antibodies for Alzheimer’s disease to patients enrolled in CMS-approved, randomized controlled trials.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters